|
Clinical activity, safety and immunogenic properties of cancer immunotherapeutic GSK2132231A in patients with unresectable and progressive metastatic cutaneous melanoma |
GSK2132231A |
111473 |
NCT00896480 2008-001301-42 |
Melanoma |
Phase 2 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. |
May 2018 |